troglitazone
Clinical trials with troglitazone (usually 200 to 600 mg/day) in patients with       type 2 diabetes mellitus consistently showed marked improvement in glycaemic       control, as well as reductions in fasting serum insulin, C-peptide and       triglyceride levels.
Clinical trials with  @SUBJECT$  (usually 200 to 600 mg/day)  @PREDICAT$  patients with        @OBJECT$  consistently showed marked improvement in glycaemic       control, as well as reductions in fasting serum insulin, C-peptide and       triglyceride levels.